Dry Eye PipeLine- AR-15512

🚨 Exciting News in Dry Eye Treatment! 🚨 Pam Theriot, OD, FAAO breaks down the latest from the hashtag#dryeye pipeline AR-15512, a promising new therapy for dry eye disease. 🌟 With rapid results in just 14 days, this novel TRPM8 receptor agonist boosts tear production, reduces pain, and maintains efficacy for up to 90 days with twice-daily use. Stay tuned for more updates on this game-changer in eye care! 👁️💧 hashtag#DryEye hashtag#Ophthalmology hashtag#Optometry hashtag#EyeCareInnovation Dr. Theriot Disclosures: Tarsus Pharmaceuticals, Inc. NuLids Bruder Healthcare NovaBay Pharmaceuticals Johnson & Johnson Vision SUN PHARMA SCOPE Eyecare & Healthcare Lumenis Captions are auto generated